Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses (2017)
- Authors:
- USP affiliated authors: AGUIAR, PATRICIA MELO - FCF ; STORPIRTIS, SILVIA - FCF
- Unidade: FCF
- DOI: 10.1016/j.critrevonc.2017.03.014
- Subjects: MIELOMA MÚLTIPLO; ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Critical Reviews in Oncology Hematology
- ISSN: 1040-8428
- Volume/Número/Paginação/Ano: v. 113, p. 195-212, 2017
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
AGUIAR, Patrícia Melo et al. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Critical Reviews in Oncology Hematology, v. 113, p. 195-212, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.critrevonc.2017.03.014. Acesso em: 19 abr. 2024. -
APA
Aguiar, P. M., Lima, T. de M., Colleoni, G. W. B., & Storpirtis, S. (2017). Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Critical Reviews in Oncology Hematology, 113, 195-212. doi:10.1016/j.critrevonc.2017.03.014 -
NLM
Aguiar PM, Lima T de M, Colleoni GWB, Storpirtis S. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses [Internet]. Critical Reviews in Oncology Hematology. 2017 ; 113 195-212.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/j.critrevonc.2017.03.014 -
Vancouver
Aguiar PM, Lima T de M, Colleoni GWB, Storpirtis S. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses [Internet]. Critical Reviews in Oncology Hematology. 2017 ; 113 195-212.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/j.critrevonc.2017.03.014 - Development and validation of key performance indicators for medication management services provided for outpatients
- Response letter to the editor Development and validation of key performance indicators for medication management services provided for outpatients"
- Perception of the patients with prostate cancer about the process of communication with the pharmacist at USP university pharmacy
- Pharmacist patient communication in prostate cancer as a strategy to humanize health hare: a qualitative study
- The effects of pharmacist interventions on adult outpatients with cancer: a systematic review
- Evaluation of quality indicator instruments for pharmaceutical care services: a systematic review and psychometric properties analysis
- Development and validation of key performance indicators for medication management services provided for outpatients
- Analysis of priorities in pharmaceutical assistance of the state of São Paulo
- Identifying quality of life indicators to improve outpatient pharmacy services for prostate cancer patients: a comparison between brazilian and british experiences
- Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews
Informações sobre o DOI: 10.1016/j.critrevonc.2017.03.014 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
